ENTX Stock Analysis: Buy, Sell, or Hold?
ENTX - Entera Bio Ltd. Ordinary Shares
$3.04
0.17 (5.92%)
▲
5d:
+2.7%
30d:
+83.69%
90d:
+133.85%
WAIT
LOW Confidence
Analysis Updated: Aug 10, 2026 12:00 AM ET
Earnings: Aug 14, 2026
2d
Get Alerted When ENTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ENTX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ENTX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ENTX is currently trading at $3.04, which is considered extended relative to its 30-day fair value range of $1.71 to $2.99.
Technical Outlook: Technically, ENTX is in a uptrend. Immediate support is located at $2.66, while resistance sits at $3.96. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: ENTX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $9.00 (+196.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ENTX is in a uptrend. Immediate support is located at $2.66, while resistance sits at $3.96. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: ENTX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $9.00 (+196.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.71 -
$2.99
Company Quality Score
37/100
(SELL)
Options IV Signal
100th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
25.0%
All Signals
- BEARISH: Price extended above range
- BEARISH: Options expensive (IV 100th percentile)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.9%)
- BULLISH: Trading 196.1% below Wall St target ($9.00)
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.71 -
$2.99
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$2.00
(65.9%)
Support & Resistance Levels
Support Level
$2.66
Resistance Level
$3.96
Current Trend
Uptrend
Technical data as of
Aug 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.33
Wall Street Target
$9.00
(+196.1%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 11, 2026 3:28 AM ET
Data refreshes hourly during market hours. Next update: 4:28 AM
Data refreshes hourly during market hours. Next update: 4:28 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENTX showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Geno J Germano
BUY
20000 shares
2026-03-09
Sean Ellis
BUY
10000 shares
2026-03-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 52 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 37 SELL |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 55 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 50 HOLD |
|
MRNA
Moderna Inc |
SELL
27 analysts |
$51 | 55 HOLD |
